Research Article

Common polymorphisms in antioxidant genes are associated with diabetic nephropathy in Type 2 diabetes patients

General Hospital Trbovlje, Rudarska cesta 9, 1420 Trbovlje, Slovenia

Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia

Search for more papers by this author

Andrej Janež

Department of Endocrinology, Diabetes & Metabolic Diseases, University Medical Center Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia

Search for more papers by this author

Vita Dolžan

*Author for correspondence:

E-mail Address: vita.dolzan@mf.uni-lj.si

Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia

Search for more papers by this author

Published Online:5 Jun 2015https://doi.org/10.2217/pme.14.86

View article

Abstract

Aim: To investigate if antioxidative genes’ polymorphisms influence the risk for Type 2 diabetes (T2D) complications. Materials & Methods: In total, 181 T2D patients were genotyped for SOD2, CAT, GPX1, GSTP1, GSTM1*0, GSTT1*0, GCLC and GCLM.Results: After adjustment for duration of T2D, CAT rs1001179 and GSTP1 rs1138272 showed strongest association with risk for end-stage kidney failure (p = 0.005 and p = 0.049, respectively). In patients without end-stage kidney failure CAT rs1001179 influenced urea levels (p = 0.003), while GSTP1 rs1695 and GSTP1 haplotypes influenced the risk of moderately increased albuminuria (p = 0.024 and p = 0.014, respectively). Conclusion: Common CAT and GSTP1 polymorphisms could be used to identify T2D patients at an increased risk for developing end-stage kidney failure.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 837–853 (1998).
MedlineGoogle Scholar
2 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10 year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008).
Medline CASGoogle Scholar
3 Park J, Lertdumrongluk P, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr. Diab. Rep. 12(4), 432–439 (2012).
Medline CASGoogle Scholar
4 Ritz E. Clinical manifestations and natural history of diabetic kidney disease. Med. Clin. North Am. 97(1), 19–29 (2013).
MedlineGoogle Scholar
5 Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in Type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in Type 2 diabetes. Arch. Intern. Med. 172(10), 761–769 (2012).
MedlineGoogle Scholar
6 Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am. J. Kidney Dis. 63(2 Suppl. 2), s63–s83 (2014).
Medline CASGoogle Scholar
7 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001).
Medline CASGoogle Scholar
8 Sasaki S, Inoguchi T. The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diab. Metab. J. 36(4), 255–261 (2012).
MedlineGoogle Scholar
9 Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85(8), 2970–2973 (2000).
Medline CASGoogle Scholar
10 Satirapoj B. Nephropathy in diabetes. Adv. Exp. Med. Biol. 771, 107–122 (2012).
MedlineGoogle Scholar
11 Stanton RC. Oxidative stress and diabetic kidney disease. Curr. Diab. Rep. 11(4), 330–336 (2011).
Medline CASGoogle Scholar
12 Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem. Biophys. Res. Commun. 433(4), 359–361 (2013).
Medline CASGoogle Scholar
13 Crawford A, Fassett RG, Geraghty DP et al. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 501(2), 89–103 (2012).
Medline CASGoogle Scholar
14 Forsberg L, De Faire U, Morgenstern R. Oxidative stress, human genetic variation, and disease. Arch. Biochem. Biophys. 389(1), 84–93 (2001).
Medline CASGoogle Scholar
15 Tang ST, Wang CJ, Tang HQ, Zhang Q, Wang Y. Evaluation of glutathione-S-transferase genetic variants affecting Type 2 diabetes susceptibility: a meta-analysis. Gene 530(2), 301–308 (2013).
Medline CASGoogle Scholar
16 Zhang J, Liu H, Yan H, Huang G, Wang B. Null genotypes of GSTM1 and GSTT1 contribute to increased risk of diabetes mellitus: a meta-analysis. Gene 518(2), 405–411 (2013).
Medline CASGoogle Scholar
17 Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol. 4(1), 5 (2005).
MedlineGoogle Scholar
18 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 35 (Suppl. 1), s64–s71 (2012) .
MedlineGoogle Scholar
19 WHO/IDF. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF Consultation (2006).
Google Scholar
20 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 130(6), 461–470 (1999).
Medline CASGoogle Scholar
21 Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes. Kidney Int. 67(6), 2089–2100 (2005).
MedlineGoogle Scholar
22 Klen J, Goričar K, Janež A, Dolžan V. The role of genetic factors and kidney and liver function in glycemic control in Type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. BioMed Res. Int. 2014, 934729 (2014).
MedlineGoogle Scholar
23 Bohanec Grabar P, Logar D, Tomsic M, Rozman B, Dolzan V. Genetic polymorphisms of glutathione-S-transferases and disease activity of rheumatoid arthritis. Clin. Exp. Rheumatol. 27(2), 229–236 (2009).
Medline CASGoogle Scholar
24 Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione-S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6(2), 187–191 (1996).
Medline CASGoogle Scholar
25 Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG. The response of antioxidant genes to hyperglycemia is abnormal in patients with Type 1 diabetes and diabetic nephropathy. Diabetes 52(3), 846–851 (2003).
Medline CASGoogle Scholar
26 Flekac M, Skrha J, Hilgertova J, Lacinova Z, Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med. Genet. 9, 30 (2008). • The study compared superoxide dismutase (SOD) and catalase genotype distribution in three relative big groups of T1D and T2D patients and controls.
MedlineGoogle Scholar
27 Panduru NM, Mota E, Mota M, Cimponeriu D, Serafinceanu C, Cheta DM. Polymorphism of catalase gene promoter in Romanian patients with diabetic kidney disease and Type 1 diabetes. Rom. J. Intern. Med. 48(1), 81–88 (2010).
Medline CASGoogle Scholar
28 Neves AL, Mohammedi K, Emery N et al. Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in Type 2 diabetic subjects. Mol. Genet. Metab. 106(3), 359–365 (2012). •• Analysis of 7 single nucleotide polymorphisms (SNPs) in SOD1 region in 3744 T2D patients from the DIABHYCAR and DIABHYCAR_GENE cohorts.
Medline CASGoogle Scholar
29 Gysin R, Kraftsik R, Boulat O et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid. Redox. Signal. 15(7), 2003–2010 (2011).
Medline CASGoogle Scholar
30 Willis AS, Freeman ML, Summar SR et al. Ethnic diversity in a critical gene responsible for glutathione synthesis. Free Radic. Biol. Med. 34(1), 72–76 (2003).
Medline CASGoogle Scholar
31 Koide S, Kugiyama K, Sugiyama S et al. Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. J. Am. Coll. Cardiol. 41(4), 539–545 (2003).
Medline CASGoogle Scholar
32 Nakamura S, Kugiyama K, Sugiyama S et al. Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. Circulation 105(25), 2968–2973 (2002).
Medline CASGoogle Scholar
33 Katakami N, Kaneto H, Matsuoka TA et al. Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese Type 2 diabetic patients. Atherosclerosis 212(2), 534–538 (2010).
Medline CASGoogle Scholar
34 Ramprasath T, Murugan PS, Kalaiarasan E, Gomathi P, Rathinavel A, Selvam GS. Genetic association of Glutathione peroxidase-1 (GPx-1) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1) variants and their association of CAD in patients with Type 2 diabetes. Mol. Cell Biochem. 361(1–2), 143–150 (2012). • The study confirmed the association of GPx-1 and NQO1 variants with coronary artery disease (CAD) in patients with T2D.
Medline CASGoogle Scholar
35 Amer MA, Ghattas MH, Abo-Elmatty DM, Abou-El-Ela SH. Evaluation of glutathione S-transferase P1 genetic variants affecting Type 2 diabetes susceptibility and glycemic control. Arch. Med. Sci. 8(4), 631–636 (2012).
Medline CASGoogle Scholar
36 Moasser E, Kazemi-Nezhad SR, Saadat M, Azarpira N. Study of the association between glutathione S-transferase (GSTM1, GSTT1, GSTP1) polymorphisms with Type 2 diabetes mellitus in southern of Iran. Mol. Biol. Rep. 39(12), 10187–10192 (2012).
Medline CASGoogle Scholar
37 Datta SK, Kumar V, Pathak R et al. Association of glutathione-S-transferase M1 and T1 gene polymorphism with oxidative stress in diabetic and nondiabetic chronic kidney disease. Ren. Fail. 32(10), 1189–1195 (2010). • The study reports association of GSTM1 and GSTT1 deletions with lower glutathione S-transferase (GST) levels and higher oxidative stress in both diabetic and nondiabetic patients with chronic kidney disease.
Medline CASGoogle Scholar
38 Pinheiro DS, Rocha Filho CR, Mundim CA et al. Evaluation of glutathione-S-transferase GSTM1 and GSTT1 deletion polymorphisms on Type 2 diabetes mellitus risk. PLoS ONE 8(10), e76262 (2013).
Medline CASGoogle Scholar
39 Cilensek I, Mankoc S, Petrovic MG, Petrovic D. GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with Type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy. Dis. Markers 32(2), 93–99 (2012).
Medline CASGoogle Scholar
40 Kariz S, Nikolajevic Starcevic J, Petrovic D. Association of manganese superoxide dismutase and glutathione-S-transferases genotypes with myocardial infarction in patients with Type 2 diabetes mellitus. Diab. Res. Clin. Pract. 98(1), 144–150 (2012).
Medline CASGoogle Scholar
41 Santl Letonja M, Letonja M, Ikolajevic-Starcevic JN, Petrovic D. Association of manganese superoxide dismutase and glutathione-S-transferases genotypes with carotid atherosclerosis in patients with diabetes mellitus Type 2. Int. Angiol. 31(1), 33–41 (2012).
Medline CASGoogle Scholar
42 Vidan-Jeras B, Jurca B, Dolan V, Jeras M, Breskvar K, Bohinjec M. Slovenian Caucasian normal. In: HLA 1998. Terasaki PI, Gjertson DW (Eds). American Society for Histocompatibility and Immunogenetics, Kansas, USA (1998).
Google Scholar
43 Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad. Med. 124(6), 90–97 (2012).
MedlineGoogle Scholar
44 Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19(3), 257–267 (1996).
Medline CASGoogle Scholar
45 Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl. Res. 159(4), 303–312 (2012).
Medline CASGoogle Scholar
46 Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol. Dial. Transplant. 27(7), 2642–2649 (2012).
MedlineGoogle Scholar
47 Battisti WP, Palmisano J, Keane WE. Dyslipidemia in patients with Type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease. Clin. Chem. Lab. Med. 41(9), 1174–1181 (2003).
Medline CASGoogle Scholar
48 Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care 34(Suppl. 2), S297–S303 (2011).
MedlineGoogle Scholar
49 Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World. J. Nephrol. 1(6), 184–194 (2012).
MedlineGoogle Scholar
50 Jardine MJ, Hata J, Woodward M et al. Prediction of kidney-related outcomes in patients with Type 2 diabetes. Am. J. Kidney Dis. 60(5), 770–778 (2012).
Medline CASGoogle Scholar
51 Jun M, Venkataraman V, Razavian M et al. Antioxidants for chronic kidney disease. Cochrane Database Syst. Rev. 10, CD008176 (2012).
MedlineGoogle Scholar

Vol. 12, No. 3

Metrics

Downloaded 80 times

History

Published online 5 June 2015

Published in print June 2015

Information

Keywords

Acknowledgements

We acknowledge the clinical nurse N Kirič for her support with clinical part of the study and S Soldat, BSc for her expert technical assistance.

Financial & competing interests disclosure

The study was financially supported by the Ministry of Education, Science, and Sport of the Republic of Slovenia (grants no. P1–0170 and P3–0298). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download